Related Experiment Video
Updated: Jun 19, 2026

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
Glutathione-Responsive Inhalable Nanotherapeutics for Targeted Macrophage Reprogramming in Chronic Obstructive
Yoogyeong Oh1,2, Taihyun Kim1, Kyungtae Park1,3
1Department of Chemical & Biomolecular Engineering, College of Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
Abstract:
Chronic inflammation of the airways plays a crucial role in disease progression and symptom exacerbation in patients with chronic obstructive pulmonary disease (COPD). Nitric oxide (NO) relaxes airway smooth muscle and regulates the inflammatory response. The multifunctional therapeutic effects of NO are highly attractive for COPD treatment. However, the practical difficulties in long-term and targeted administration remain a limitation. This work presents an inhaled nanotherapeutic, termed AIR (Anti-Inflammatory Relaxer), engineered for targeted NO delivery to proinflammatory M1 macrophages. AIR is constructed from dendritic mesoporous silica nanoparticles (DMSNs) functionalized with hyaluronic acid (HA) and diazeniumdiolates (NONOates). HA enables selective targeting of CD44-overexpressing M1 macrophages, thereby leading to their polarization into anti-inflammatory phenotypes. Moreover, disulfide bonds in AIR are cleaved by intracellular glutathione, which is present at millimolar concentrations, ensuring excellent biocompatibility. Overall, these inhaled nanotherapeutics have great potential in relieving chronic inflammation in COPD while reducing bioaccumulation in the lungs.
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
